» Articles » PMID: 37176642

The Association Between Autoimmune Thyroid Disease and Ocular Surface Damage: A Retrospective Population-Based Cohort Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 May 13
PMID 37176642
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune thyroid diseases (ATDs) are potentially connected to lacrimal gland dysfunction and ocular surface disruption. This study aimed to evaluate the relationships between ATD, dry eye disease (DED), and corneal surface damage. In a matched nationwide cohort study, we used Taiwan's National Health Insurance research database to compare the incidences of DED and corneal surface damage between subjects with and without ATD. Multivariable Cox proportional hazards regression models were used to estimate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for the ophthalmological outcomes. A total of 50,251 matched pairs with 748,961 person-years of follow-up were included for analysis. The incidence of DED was 16.37 and 8.36 per 1000 person-years in the ATD and non-ATD groups, respectively. ATDs were significantly associated with increased DED (aHR: 1.81, 95% CI: 1.73-1.89, < 0.0001). This association was generally consistent across the subgroups of age, sex, different comorbidity levels, and use of systemic corticosteroids or not. Furthermore, patients with ATD had a higher risk of corneal surface damage compared with non-ATD subjects (aHR: 1.31, 95% CI: 1.19-1.44, < 0.0001), including recurrent corneal erosions (aHR: 2.00, 95% CI: 1.66-2.41, < 0.0001) and corneal scars (aHR: 1.26, 95% CI: 1.01-1.59, = 0.0432). Other independent factors for corneal surface damage were age, sex, diabetes mellitus, Charlson Comorbidity Index scores, and use of systemic corticosteroids. Our results suggested that ATDs were associated with higher risks of DED and corneal surface damage. Considering the high prevalence of ATD, prophylactic and therapeutic strategies should be further developed to prevent irreversible vision loss in this susceptible population.

Citing Articles

Research progress on the immune mechanism of thyroid-related eye disease combined with dry eye.

Wang Y, Chen D, Jin L, Li D J Ophthalmic Inflamm Infect. 2025; 15(1):23.

PMID: 40063329 PMC: 11893917. DOI: 10.1186/s12348-025-00477-7.


Advances of IGF-1R inhibitors in Graves' ophthalmopathy.

Wang M, Liu L Int Ophthalmol. 2024; 44(1):435.

PMID: 39578269 DOI: 10.1007/s10792-024-03358-5.


Inflammatory bowel disease and the associated risk of dry eye and ocular surface injury: a nationwide matched cohort study.

Ko Y, Wu Y, Wu H, Lai S, Dai Y, Chen T BMC Ophthalmol. 2023; 23(1):415.

PMID: 37833664 PMC: 10576268. DOI: 10.1186/s12886-023-03165-z.

References
1.
Antonelli A, Ferrari S, Ragusa F, Elia G, Paparo S, Ruffilli I . Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020; 34(1):101387. DOI: 10.1016/j.beem.2020.101387. View

2.
Ajjan R, Weetman A . The Pathogenesis of Hashimoto's Thyroiditis: Further Developments in our Understanding. Horm Metab Res. 2015; 47(10):702-10. DOI: 10.1055/s-0035-1548832. View

3.
Vehof J, Snieder H, Jansonius N, Hammond C . Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. Ocul Surf. 2020; 19:83-93. DOI: 10.1016/j.jtos.2020.04.005. View

4.
Kan E, Kilickan E, Ecemis G, Beyazyildiz E, Colak R . Presence of Dry Eye in Patients with Hashimoto's Thyroiditis. J Ophthalmol. 2015; 2014:754923. PMC: 4279782. DOI: 10.1155/2014/754923. View

5.
Rana H, Akella S, Clabeaux C, Skurski Z, Aakalu V . Ocular surface disease in thyroid eye disease: A narrative review. Ocul Surf. 2022; 24:67-73. PMC: 9058200. DOI: 10.1016/j.jtos.2022.02.001. View